AIVITA Biomedical Executes Deal with Lacore Labs for Asian Distribution of a New Skincare Line

New skincare products to be distributed through greater Asian countries including Hong Kong, Taiwan, Singapore, Malaysia and Mainland China

IRVINE, Calif. – December 07, 2017 – AIVITA Biomedical today announced the execution of a deal with custom formulator and beauty product developer Lacore Laboratories. The deal allows for the use of AIVITA’s proprietary actives complex in a new line of skincare products to be distributed by Lacore’s subsidiary Generation New Online across greater Asian countries. Consumers in Hong Kong, Taiwan, Singapore, Malaysia and Mainland China will be among the first to have access to the new line.

AIVITA’s proprietary active technology is a science-based multi-functional ingredient complex and delivery system which captures the natural cell messaging system and ingredients of skin stem cells. The active contains a complete and balanced mix of all the naturally-occurring, revitalizing factors present in a young skin environment.

“Lacore brings unique capabilities to AIVITA, including their cultural knowledge of product preferences and their distribution prowess throughout Asia”, said Dr. Hans Keirstead, Chairman and CEO of AIVITA Biomedical, “We’re thrilled to be bringing our revolutionary active technology to consumers throughout the world”.

Sales of AIVITA’s skincare products support the Company’s clinical cancer development programs, including an active Phase 2 clinical trial for women with ovarian cancer.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial line of skin care products and therapeutic pipeline. Sales of AIVITA’s skin care products support its clinical development efforts, including a platform cancer immunotherapy.